– New clinical data across ten accepted abstracts demonstrate significant progress across Astellas’ innovative oncology programs – – Results from the EV-303 trial (also known as KEYNOTE-905) in cisplatin-ineligible patients with muscle invasive bladder cancer […]
TOKYO, Sept. 29, 2025 /PRNewswire/ — Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, “Astellas”) today announced the following changes to its Top Management structure, effective October 1, 2025. Nick Eshkenazi, current Chief Digital & Transformation Officer (CDTO), […]
TOKYO, Oct. 10, 2024 /PRNewswire/ — Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, “Astellas”) announced that VEOZA™ (fezolinetant)*, its first-in-class treatment for moderate to severe vasomotor symptoms (VMS) associated with menopause, will be featured […]
– New digital health solution for heart failure management puts patients at the center of their care by providing ability for at-home disease monitoring – TOKYO, Sept. 18, 2024 /PRNewswire/ — Astellas Pharma Inc. (TSE: […]
– HIGHLIGHT 1™ study to evaluate fezolinetant for treatment of moderate to severe vasomotor symptoms in women with stage 0-3 hormone receptor positive breast cancer receiving adjuvant endocrine therapy – TOKYO, Aug. 27, 2024 /PRNewswire/ — […]
